BRCC3 mutations in myeloid neoplasms

SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Hyper eosinophilia associated with myeloid and lymphoid neoplasms

Eosinophilia in the absence of allergies, asthma, drug reactions, parasitic infections and connective tissue diseases can be eosinophilic clonal disorders, lymphoma or myeloproliferative disorders. Hypereosinophilia with the persistence of eosinophils ≥1500 /mm³ in blood or more than 20% of eosinophils in the bone marrow may be observed in many reactive or clonal disorders, the result of which ...

Therapy-related myeloid neoplasms.

Session 5 of 2007 Workshop of the Society for Hematopathology/European Association for Haematopathology focused on therapy-related myeloid neoplasms. This report discusses the diversity and relevance of clinical, pathologic, and genetic features and provides an update on the pathogenesis of these disorders. We highlight common diagnostic issues such as the differentiation between therapy-relate...

Therapy - related myeloid neoplasms

Professor Eliane Gluckman is Past Head of the Hematology Bone Marrow Transplantation Unit, Hospital Saint Louis, Paris and currently Professor Emeritus of University Paris VII, Director of Eurocord, and President of the European School of Haematology. Dr. Vanderson Rocha is Scientific Director of Eurocord, Chair of the Acute Leukemia Working Party of EBMT and medical assistant of the HSCT unit ...

Therapy-Related Myeloid Neoplasms

Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2 3/100.000/year in developed countries. With modern multi optionally combined with radiotherapy (RT), 80% to 90% of HL patients achieve long remission and can be considered cured. However, current standard approaches bear a considerable risk for the development of treatment research in HL is reducing the inciden...